The other issue is that DCVAX data will be compared to actual prior trial results with similar "cherry picked" selection criteria, and we know from LL's recent talk what those pooled numbers look like. DCVAX trial data clearly exceed these historical controls that will be used for comparison. Excluding people who are not GBM or who have insufficient tumor lysate will not change the OS results - these are random factors that would not alter OS.
I think it is rich of the shorts and commercial rivals to suggest that a treatment needing to have patients with larger, juicier tumors is cherry-picking.
News 
Market Data 
Discover 
